New initiatives, faster Sputnik rollout can lift DRL

The company’s management has also alluded to DRL experimenting with forays into nutrition, direct-to-customer and digital health & wellness.

Synopsis
Revenues rose 12% and net profit declined by a percent over the prior year. Ebitda margin dropped 560 bps to 20.7%. The disappointing performance was caused by underperformance of the US and API businesses. Profitability was impacted due to price erosion, increase in inventory provisions related to few products and higher other expenditure.

ET Intelligence Group: The June-quarter performance of drug major Dr Reddy’s Labs (DRL) turned out to be a washout for the Street. What aggravated matters further was the company getting a subpoena from the US market regulator to furnish documents on certain CIS geographies in relation to the complaint that alleged payments to healthcare professionals in violation of US anti-corruption laws were made. This caused the DRL stock to slump more

Kiran Kabtta Somvanshi

ET Bureau

4 mins read, Last Updated:

Jul 28, 2021, 07:10 AM IST

Share This Article

GIFT ARTICLE
FONT SIZE
AbcSmall
AbcMedium
AbcLarge
SAVE
PRINT
COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

₹399/month

Monthly PLAN

Billed Amount ₹399

No Trial Period

~~₹399~~

₹208/month

(Save 49%)

Yearly PLAN

Billed Amount ₹2,499

15 Days Trial +Includes DocuBay and TimesPrime Membership.

~~₹399~~

₹150/month

(Save 63%)

2-Year PLAN

Billed Amount ₹3,599

15 Days Trial +Includes DocuBay and TimesPrime Membership.

MEGA MONSOON OFFER - Last 2 Days Left

GET 30% DISCOUNT

ON ET PRIME MEMBERSHIP

Get Offer

Why ?

Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community
Exclusive invites to Virtual Events with Industry Leaders
A trusted team of Journalists & Analysts who can best filter signal from noise